Brief: Pds Biotechnology Expanded Interim Data In Phase 2 Clinical Trial Investigating Pds0101-Based Triple Combination Therapy
28/12/2022 13:13
Dec 28 (Reuters) - PDS Biotechnology Corp PDSB.O :
* PDS BIOTECHNOLOGY -EXPANDED INTERIM DATA IN A PHASE 2
CLINICAL
TRIAL INVESTIGATING PDS0101-BASED TRIPLE COMBINATION THERAPY IN
ADVANCED HUMAN PAPILLOMAVIRUS-POSITIVE CANCERS
* PDS BIOTECHNOLOGY-EXPANDED INTERIM DATA IN PHASE 2
CLINICAL
TRIAL INVESTIGATING PDS0101-BASED TRIPLE COMBINATION THERAPY IN
ADVANCED HPV POSITIVE CANCERS
Source text for Eikon: ID:nGNX1BT43p
Further company coverage: PDSB.O
((reuters.briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing